$104.84+$2.74 (+2.68%) on the dayAs of the close; data may be delayed.
GRAL price, last 12 months
$158.92$43.03$104.84
Daily closes over the last 260 trading sessions: +32.0%. Highest close $158.92 on , lowest $43.03 on . Market data may be delayed.
Key stats
Previous close
$102.10
Open
$105.00
Day range
$103.29 – $111.50
52-week range
$41.50 – $166.48
Volume
797.6K
Avg volume (20 days)
906.5K
Market cap
$5.2B
Performance
1W−14.4%
1M−21.9%
3M+29.6%
6M+47.7%
YTD+16.0%
1Y+12.8%
vs S&P 500, 1Y+8.7 pts
Technicals and fundamentals
About GRAIL, Inc.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Chart GRAL with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full GRAL chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)10.6%average true range, % of price
52w low $41.5052w high $166.48
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−12.2
PEG—
Price / sales26.98
Price / book1.81
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusBuy2.0 on 1 (strong buy) to 5 (strong sell)
Analysts9
Average target$139.44+40.5% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Jan 11, 2027 (in 51 days)A year after its Jan 12, 2026 results release; the last came Nov 4, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
+42.0
J
-9.1
F
-18.3
M
+20.2
A
+21.5
M
+14.6
J
-11.0
J
+1.1
A
+51.5
S
+18.8
O
+24.5
N
-10.2
D
Average return in each calendar month, Jul 31, 2024 to Oct 31, 2026. 3 years is 3 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+14
−46
−3
+5
+32
−5
+0
+16
+77
+2
+68%
2025
+70
+27
−34
+35
+11
+34
−33
−4
+80
+55
+20
−22
+380%
2024
+0
−8
−2
−1
+29
+2
+16%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Positive FDA advisory committee vote supports path to first-ever FDA-approved multi-cancer screening test by early 2027. Strong Q3 test volume growth (24% YoY), solid cash position ($788.7M), and clear pathway to 50-60% gross margins at scale demonstrate solid long-term fundamentals despite near-term margin sacrifice for market penetration.
While the stock received a positive catalyst from FDA panel approval and surged 80%, the article highlights a significant downside risk regarding pricing negotiations with insurers. The positive regulatory development is tempered by uncertainty around whether insurers will accept the $949 price point, making the overall outlook balanced rather than clearly positive or negative.
Company shows strong revenue growth (58% increase from 2023-2025), recent FDA panel endorsement for premarket approval, expanding test volumes (42% YoY growth), and potential for significant market expansion upon FDA approval. Stock trading near all-time highs with analyst expectations for continued growth.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.